AUPH — Aurinia Pharmaceuticals Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1600620 ·
Last close
$15.82
Market Cap
$2.03B
52W High
$16.88
52W Low
$13.81
ADV30
1,267,070
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 77,705,000 | 71,200,000 | 41,422,000 | 34,355,000 | 723,997,000 | 41,008,000 | 156,371,000 |
| Dec 2025 | 77,114,000 | 68,315,000 | 33,239,000 | 210,794,000 | 751,587,000 | 80,213,000 | 170,256,000 |
| Sep 2025 | 73,468,000 | 65,291,000 | 29,745,000 | 31,551,000 | 527,528,000 | 73,189,000 | 161,757,000 |
| Jun 2025 | 70,008,000 | 62,893,000 | 20,197,000 | 21,513,000 | 502,562,000 | 53,002,000 | 167,261,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$166,918,000
Investing CF
$-81,880,000
Financing CF
$-110,458,000
CapEx
$-274,000
Dividends Paid
—
Buybacks
$-87,400,000
EPS Diluted TTM
$2.17
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-615,013,000
Inventory
$46,410,000
Receivables
$49,175,000
ST Investments
$337,775,000
EBIT TTM
$138,008,000
Pretax Income TTM
$133,733,000
Interest Exp TTM
$4,275,000
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$298,295,008
EBITDA
$153,712,000
Free Cash Flow
$124,632,496
Enterprise Value
$1,724,594,432
Total Cash
$378,524,000
Total Debt
$68,640,000
Shares Out
128,601,671
Trailing EPS
$2.16
Book Value
$4.34
ROE
65.0%
ROA
13.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 283,055,000 | 106,561,000 | 287,202,000 | 751,587,000 | 170,256,000 | — | 135,658,000 |
| Dec 2024 | 235,133,000 | 18,419,000 | 5,752,000 | 550,645,000 | 173,167,000 | — | 44,388,000 |
| Dec 2023 | 175,513,000 | -91,691,000 | -78,020,000 | 548,062,000 | 170,108,000 | — | -33,461,000 |
| Dec 2022 | 134,030,000 | -111,470,000 | -108,180,000 | 470,860,000 | 65,425,000 | — | -79,529,000 |
TTM Snapshot
Revenues TTM
$178,065,000
NetIncome TTM
$-8,086,000
OpCashFlow TTM
$0
Assets (Latest)
$550,645,000
Forward EPS
$1.12
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TRVI | Trevi Therapeutics, Inc. | $2.02B | $14.21 | — |
| NKTR | NEKTAR THERAPEUTICS | $2.01B | $59.38 | — |
| HRMY | Harmony Biosciences Holdings, Inc. | $1.99B | $34.46 | — |
| IMNM | Immunome Inc. | $2.08B | $18.38 | — |
| MLYS | Mineralys Therapeutics, Inc. | $2.08B | $23.62 | — |
News headlines (Yahoo Finance, 1h cache)
Aurinia Pharmaceuticals and Four More Stocks See Activist Action
2026-06-12 22:47 · Yahoo
A Fresh Look At Aurinia Pharmaceuticals (AUPH) Valuation After Recent Share Price Consolidation
2026-06-11 14:11 · Yahoo
Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million
2026-06-07 12:17 · Yahoo
LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death
2026-06-04 11:00 · Yahoo
TANG CAPITAL MANAGEMENT, LLC FILES EARLY WARNING REPORT RESPECTING AURINIA PHARMACEUTICALS INC.
2026-06-03 04:43 · Yahoo
Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences
2026-05-19 12:30 · Yahoo
We Believe Aurinia Pharmaceuticals' (NASDAQ:AUPH) Earnings Are A Poor Guide For Its Profitability
2026-05-15 10:38 · Yahoo
Aurinia Pharmaceuticals Inc. Just Beat EPS By 28%: Here's What Analysts Think Will Happen Next
2026-05-09 13:23 · Yahoo
Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top Estimates
2026-05-07 15:15 · Yahoo
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress
2026-05-07 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.